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What is new? 
 An extension to the CONSORT statement to guide the reporting of randomized pilot and 
feasibility trials has been published. 
 Use of the statement should improve transparency and completeness of reporting. 
 Standards of reporting are unlikely to improve unless adoption of guidelines is actively 
encouraged. 
 Funders, journal editors and researchers should collaborate to develop and test methods for 
encouraging the use of reporting guidelines. 
Introduction 
Poor reporting is one of the main reasons why much research effort is wasted.[1] Another is 
inadequate feasibility testing and piloting before an efficacy or effectiveness study is conducted.[2] A 
new extension to the CONSORT statement seeks to improve the way randomized pilot and feasibility 
trials are reported.[3][4] Adoption of the extension by journals that publish such trials should 
encourage its use by researchers, directly improving standards of reporting, and indirectly improving 
the way pilot and feasibility trials are designed and conducted. 
Why was the extension needed? 
Thorough feasibility testing and piloting should reduce the number of full scale efficacy or 
effectiveness trials that fail outright or are delayed due to unforeseen problems with recruitment or 
retention of participants, delivery of the intervention, and other aspects of study implementation. It 
may also help to reduce the number of efficacy or effectiveness trials that produce inconclusive 
findings due to unrealistic expectations about size or variability of effects. 
Until recently there was little explicit guidance or support for pilot or feasibility trials. The UK 
Medical Research Council (MRC) guidance for the development and evaluation of complex 
interventions emphasised the need for careful development and piloting, and clearly demarcated 
this work from later phases in the research process, but did not clearly distinguish between pilot and 
feasibility studies.[5] It may therefore have inadvertently contributed to the terminological 
confusion that has dogged this area. The CONSORT extension sidesteps these problems by noting 
that the same reporting requirements apply to any small scale trial that seeks to determine whether 
and how an efficacy or effectiveness trial should be conducted, and proposes the term ‘pilot trial’ to 
cover all such studies. 
In the last few years recognition of the importance of pilot trials has grown. A number of reviews of 
existing practice have been published,[2][6][7] and some funders have developed guidance for 
applicants or explicitly set aside funding for such work.[8] Development of the extension has inspired 
the establishment of a journal, Pilot and Feasibility Studies, which publishes pilot trials and seeks to 
provide ‘a forum for discussion of methodological issues that will lead to increased scientific rigour 
in this area.’[9] 
What does the extension add? 
The extension adopts 14 of the 37 CONSORT items unchanged, identifies two as inapplicable to pilot 
trials, adds three new items, and modifies the remainder. It also incorporates a revised CONSORT 
statement for abstracts and revised flow diagram for describing how participants progress through 
the trial. Many of the changes to the CONSORT items aim to identify pilot trials clearly, and 
distinguish them from efficacy or effectiveness studies. For example, item 1a of the extension reads 
‘Identification as a pilot or feasibility randomized trial in the title’ (additions in italics). These changes 
are more than nominal: pilot trials have distinct aims, which are reflected in the way the data should 
be analysed and interpreted. 
The distinction between the aims of a pilot and an efficacy or effectiveness trial is reflected in 
changed items 17(a)  and 18, and excluded items 12b and 17b (Table 1). In presenting the results of 
a pilot trial, the aim of including measures of uncertainty (item 17a) is to highlight the imprecision of 
estimates from a small sample, rather than to support interpretation of effect sizes. The distinction 
between absolute and relative effects (item 17b) reflects their differing clinical or policy meanings, 
so is not relevant to the interpretation of results from a pilot trial. Estimates from a pilot trial should 
only be used as inputs to the design of a future effectiveness study, and even then should only be 
used alongside other information, such as previous trial results and judgements about the minimum 
clinically meaningful effect.[10] Likewise, the modification to item 18 reflects the exploratory nature 
of a feasibility trial, which makes the distinction between exploratory analyses and prespecified or 
subgroup analyses less important. Item 12b is deemed inapplicable for similar reasons. 
Table 1 Revised CONSORT items relating to the analysis of pilot trials 
Outcomes and 
estimation: 
 CONSORT Extension for pilot trials 
12b Methods for additional analyses, 
such as subgroup analyses and 
adjusted analyses 
Not applicable 
17a For each primary and secondary 
outcome, results for each group, and 
the estimated effect size and its 
precision (such as 95% confidence 
interval)   
For each prespecified objective, 
results including expressions of 
uncertainty (such as 95% confidence 
interval) for any estimates. If 
relevant, these results should be by 
randomized group 
17b For binary outcomes, presentation 
of both absolute and relative effect 
sizes is recommended 
Not applicable 
Ancillary analyses:     
18 Results of any other analyses 
performed, including subgroup 
analyses and adjusted analyses, 
distinguishing prespecified from 
exploratory 
Results of any other analyses 
performed that could be used to 
inform the future definitive trial 
 
The three new items (4c, 19a, and 26) in the extension are in principle applicable both to efficacy or 
effectiveness trials and to pilot trials. Item 4c, ‘how participants were identified and consented,’ is 
particularly salient to pilot trials given their role in testing recruitment procedures. Likewise, item 
19a, ‘If relevant, other important unintended consequences,’ could apply to any trial, but is crucial to 
the role of pilot trials in anticipating what may happen in a future larger scale trial. Item 26, ‘Ethical 
approval/research review committee approval confirmed with reference number,’ seems equally 
important to both pilot and efficacy or effectiveness trials. 
What effect will the extension have? 
CONSORT has been endorsed by over 600 medical journals, and the main CONSORT papers have 
been cited more than 8000 times. Despite this, its influence is surprisingly weak. The CONSORT 
website acknowledges that ‘Even among endorsing journals the reporting of key methodological 
items was still dismal.’[11] Only a small minority of CONSORT Items are significantly better reported 
in endorsing than in non-endorsing journals, and few are reported significantly better after 
endorsement by a journal than they were before endorsement. These kinds of comparisons are 
obviously subject to confounding and endogeneity, so the actual impact may be still smaller.[12] 
Part of the reason for the lack of improvement may be that endorsement often does not amount to 
much. According to the CONSORT website, endorsement ‘typically occurs in the form of a supportive 
statement.’ Information on additional procedures used by endorsing journals to enforce compliance 
is scarce. Ironically, for a guideline designed to support the reporting of randomized trials, there 
have been very few randomized studies of the impact of procedures for improving compliance with 
CONSORT, or with other reporting guideline.[13] 
Publication of the CONSORT extension for pilot trials is an important step forward. For the extension 
to have a significant impact, action must also be taken to encourage compliance. The most 
persuasive evidence of the impact of using the guideline on reporting quality will come from trials of 
methods for encouraging use of guidance. Journals that publish CONSORT statements and benefit 
from the citations that such papers attract should be willing to support the conduct of such trials, 
and to publish the results. Research funders, much of whose investment in trials is squandered by 
poor reporting,[1] should be willing to help meet the costs. Trial methodologists should be willing to 
contribute their expertise to the design and running of the trials. 
What else is needed to improve the conduct of pilot trials? 
As well as directly influencing quality of reporting of pilot trials, the extension may also help to 
improve standards of design and conduct. It provides a checklist of design elements that researchers 
should consider in developing proposals for pilot trials. Reports of pilot trials based on the extension 
will provide exemplars that other researchers can use as a guide. However there are a number of 
uncertainties about the design of such early stage studies that still need to be resolved. They 
include: how to strike the right balance between intervention development and evaluation design; 
how to decide whether randomisation is needed; how progression criteria should be defined and 
applied; and what role (if any) pilot trial findings should play in determining the sample size for a 
future efficacy or effectiveness trial. The UK MRC has recently funded two studies, INDEX, which 
focuses on the developmental stage, and GUEST, which addresses the pilot and feasibility stage. The 
studies will seek to identify the consensus among researchers, funders and journal editors about 
good practice, and to develop and disseminate methodological guidance  
Conclusion 
If pilot trials came of age with the launch of Pilot and Feasibility Studies, the publication of the 
CONSORT extension is another important step towards maturity. Its impact will depend on whether 
journals are willing to go beyond passive endorsement towards active promotion of its use by 
authors and reviewers. 
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